Subgroup analysis based on treatment regimens (anti-PD-1 as monotherapy vs. chemo-immuno combination) revealed that LOX-1+PMN-MDSCs serve as prognostic biomarker in chemo-immunotherapy treated patients, which is the therapy of choice for HNSCC patients. The gene discussed is OLR1; the disease is head and neck squamous cell carcinoma.